StockData
Viking Therapeutics, Inc. logo

Viking Therapeutics, Inc. (VKTX) stock

VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/30
$24.77−1.07 (-4.14%)

Close on Nov 20, 2026Market cap $3.16BP/E –Yield –

Viking Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

No free cash flow figures for Viking Therapeutics

Viking Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Viking Therapeutics figures

See a number that looks wrong?